Bristol-Myers Squibb Co (NYSE:BMY) Position Cut by V Wealth Advisors LLC

V Wealth Advisors LLC trimmed its holdings in Bristol-Myers Squibb Co (NYSE:BMY) by 31.5% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 4,751 shares of the biopharmaceutical company’s stock after selling 2,188 shares during the quarter. V Wealth Advisors LLC’s holdings in Bristol-Myers Squibb were worth $279,000 at the end of the most recent reporting period.

A number of other hedge funds have also modified their holdings of the stock. Ellevest Inc. lifted its position in Bristol-Myers Squibb by 32.3% in the second quarter. Ellevest Inc. now owns 2,047 shares of the biopharmaceutical company’s stock worth $120,000 after purchasing an additional 500 shares during the period. Benedict Financial Advisors Inc. lifted its position in Bristol-Myers Squibb by 1.2% in the second quarter. Benedict Financial Advisors Inc. now owns 44,064 shares of the biopharmaceutical company’s stock worth $2,591,000 after purchasing an additional 510 shares during the period. Monetary Management Group Inc. lifted its position in Bristol-Myers Squibb by 8.9% in the first quarter. Monetary Management Group Inc. now owns 47,087 shares of the biopharmaceutical company’s stock worth $2,625,000 after purchasing an additional 3,850 shares during the period. Venture Visionary Partners LLC lifted its position in Bristol-Myers Squibb by 6.2% in the first quarter. Venture Visionary Partners LLC now owns 4,359 shares of the biopharmaceutical company’s stock worth $242,000 after purchasing an additional 255 shares during the period. Finally, Kistler Tiffany Companies LLC lifted its position in Bristol-Myers Squibb by 22.4% in the second quarter. Kistler Tiffany Companies LLC now owns 17,830 shares of the biopharmaceutical company’s stock worth $1,048,000 after purchasing an additional 3,268 shares during the period. 74.20% of the stock is owned by institutional investors and hedge funds.

NYSE BMY opened at $58.66 on Friday. Bristol-Myers Squibb Co has a 1-year low of $44.00 and a 1-year high of $68.34. The company has a current ratio of 1.66, a quick ratio of 1.51 and a debt-to-equity ratio of 0.86. The company has a market capitalization of $132.73 billion, a PE ratio of 72.42, a price-to-earnings-growth ratio of 1.12 and a beta of 0.73. The firm’s fifty day simple moving average is $58.18 and its 200-day simple moving average is $60.16.

Bristol-Myers Squibb (NYSE:BMY) last posted its quarterly earnings results on Thursday, May 7th. The biopharmaceutical company reported $1.72 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.49 by $0.23. Bristol-Myers Squibb had a net margin of 3.08% and a return on equity of 30.06%. The business had revenue of $10.78 billion for the quarter, compared to the consensus estimate of $10.04 billion. During the same period in the prior year, the business posted $1.10 earnings per share. Bristol-Myers Squibb’s revenue for the quarter was up 82.1% compared to the same quarter last year. As a group, analysts predict that Bristol-Myers Squibb Co will post 6.18 EPS for the current year.

The business also recently declared a quarterly dividend, which will be paid on Monday, August 3rd. Stockholders of record on Monday, July 6th will be paid a $0.45 dividend. This represents a $1.80 dividend on an annualized basis and a dividend yield of 3.07%. The ex-dividend date of this dividend is Thursday, July 2nd. Bristol-Myers Squibb’s dividend payout ratio (DPR) is presently 38.38%.

BMY has been the subject of a number of recent research reports. Cfra reiterated a “buy” rating and set a $70.00 price objective on shares of Bristol-Myers Squibb in a research report on Sunday, July 26th. Zacks Investment Research downgraded Bristol-Myers Squibb from a “buy” rating to a “hold” rating and set a $66.00 price objective for the company. in a research report on Thursday, April 16th. Bank of America reiterated a “buy” rating and set a $80.00 price objective on shares of Bristol-Myers Squibb in a research report on Friday, May 15th. ValuEngine downgraded Bristol-Myers Squibb from a “sell” rating to a “strong sell” rating in a research report on Monday, June 1st. Finally, TheStreet downgraded Bristol-Myers Squibb from a “b-” rating to a “c+” rating in a research report on Monday, April 13th. One analyst has rated the stock with a sell rating, four have issued a hold rating and thirteen have given a buy rating to the company’s stock. Bristol-Myers Squibb presently has an average rating of “Buy” and an average target price of $68.93.

In other Bristol-Myers Squibb news, EVP Louis S. Schmukler sold 25,000 shares of the stock in a transaction on Tuesday, May 19th. The shares were sold at an average price of $62.68, for a total transaction of $1,567,000.00. Following the transaction, the executive vice president now directly owns 26,777 shares of the company’s stock, valued at $1,678,382.36. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Dinesh C. Paliwal bought 9,174 shares of the stock in a transaction on Monday, June 15th. The shares were acquired at an average cost of $54.50 per share, for a total transaction of $499,983.00. Following the completion of the transaction, the director now directly owns 22,109 shares of the company’s stock, valued at $1,204,940.50. The disclosure for this purchase can be found here. Corporate insiders own 0.14% of the company’s stock.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers drugs in oncology, immunoscience, cardiovascular, and fibrotic diseases. The company's products include Opdivo, a biological product for anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in adult patients with non-valvular atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders; and Orencia, a biological product for adult patients with moderately to severely active RA and prostate-specific antigen, as well as reducing signs and symptoms in certain pediatric patients with moderately to severely active polyarticular juvenile idiopathic arthritis.

See Also: High-Yield Dividend Stocks

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Co (NYSE:BMY).

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.